Opinion|Videos|August 22, 2024
Clinical Implications of Updated Data from EHA 2024
Author(s)Rafael Fonseca, MD, Binod Dhakal, MD, MS
Key opinion leaders evaluate the clinical implications of updated data presented at EHA 2024, interpreting how these findings may influence future treatment strategies in multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What Is your current strategy and treatment option for maintenance therapy in NDMM for transplant eligible??
- Please share your thoughts on the updated data from CASSOPEIA. (M
oreau P et al. EHA 2024, Abstract S204 ) - How does the data impact frontline treatment for transplant eligible NDMM?
Advertisement
Related to this article
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
2
What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism
3
Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC
4
Rethinking Patient Selection Strategy for Phase 1 Breast Cancer Trials
5